Genomic, proteomic and metabolomic study of gastrointestinal tissue for patients with type 2 diabetes mellitus after Roux-en-Y gastric bypass

• Grant number: 14/07742-5
• Support Opportunities: Scholarships abroad - Research Internship - Doctorate (Direct)
• Effective date (Start): January 12, 2015
• Effective date (End): April 09, 2015
• Field of knowledge: Health Sciences - Nutrition - Nutrition Biochemistry
• Principal Investigator: Dan Linetzky Waitzberg
• Grantee: Priscila Sala Kobal
• Supervisor: Steven B. Heymsfield
• Host Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Research place: Pennington Biomedical Research Center, United States
• Associated to the scholarship: 13/03246-0 - Genomic, proteomic and metabolomic study of gastrointestinal tissue for patients with type 2 Diabetes mellitus after Roux-en-Y gastric bypass, BP.DD

Abstract

Type 2 diabetes mellitus (T2DM) is a relevant public health and obesity has been associated as the major risk factor. Roux-en-Y gastric bypass is an effective method to treat severe obesity, and its metabolic benefits lead to early and complete remission of T2DM, even before a considerable weight loss. Experimentally, the anatomical changes induced by RYGB can change genes expression in gastrointestinal tissue related to glucose control determinants to T2DM reversal. However, there aren't clinical studies that prove these findings in humans. Some gastrointestinal hormones already have been studied as possible mediators of glycemic control improvement after metabolic surgery, such as, ghrelin, peptide YY, enteroglucagon and incretins (GLP-1 and GIP). Due to endocrine effects of Roux-en-Y gastric bypass, it is reasonable to believe that other hormones and mechanisms are involved in glycemic homeostasis after surgery. The genomic, proteomic and metabolomics studies of gastrointestinal tissue in T2DM patients after Roux-en-Y gastric bypass can provide a better understanding of the T2DM pathophysiology enabling the study of new therapeutic targets for the treatment of this clinical condition. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

SALA, PRISCILA; MACHADO, NATASHA MENDONCA; TORRINHAS, RAQUEL SUSANA MATOS DE MIRANDA; FONSECA, DANIELLE C.; FERREIRA, BEATRIZ A. M.; ISHIDA, ROBSON KIYOSHI; GUARDA, ISMAEL FRANCISCO MOTA SIQUEIRA; DE MOURA, EDUARDO GUIMARAES HOURNEAUX; SAKAI, PAULO; SANTO, MARCO AURELIO; et al. Genetic reprogramming of rHemnant duodenum may contribute to type 2 diabetes improvement after Roux-en-Y gastric bypass. NUTRITION, v. 99-100, p. 10-pg., 2022-04-28. (13/03246-0, 11/09612-3, 14/07742-5)

SALA, PRISCILA; BELARMINO, GILIANE; MACHADO, NATASHA MENDONCA; CARDINELLI, CAMILA SIQUEIRA; AL ASSAL, KARINA; SILVA, MARIANE MARQUES; FONSECA, DANIELLE CRISTINA; ISHIDA, ROBSON KIYOSHI; SANTO, MARCO AURELIO; HOURNEAUX DE MOURA, EDUARDO GUIMARAES; et al. The SURMetaGIT study: Design and rationale for a prospective pan-omics examination of the gastrointestinal response to Roux-en-Y gastric bypass surgery. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, v. 44, n. 6, p. 1359-1375, DEC 2016. (15/22820-5, 11/09612-3, 14/05220-1, 13/03246-0, 14/07742-5, 12/23762-0, 16/01259-6, 13/23355-9)